During the past decade, Centro Ricerche Cliniche di Verona conducted 22 clinical trials. In the 10-year time frame, 22 clinical trials started and 5 clinical trials were completed, i.e. on average, 22.7% percent of trials that started reached the finish line to date. In the past 5 years, 19 clinical trials started and 3 clinical trials were completed. i.e. 15.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centro Ricerche Cliniche di Verona" #1 sponsor was "Incyte Corporation" with 4 trials, followed by "Italfarmaco" with 2 trials sponsored, "ReiThera Srl" with 2 trials sponsored, "Amgen" with 1 trials sponsored and "Arena Pharmaceuticals" with 1 trials sponsored. Other sponsors include 10 different institutions and companies that sponsored additional 20 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centro Ricerche Cliniche di Verona" #1 collaborator was "Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani" with 2 trials as a collaborator, "Aptuit" with 1 trials as a collaborator, "Arena is a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator, "BeiGene, Ltd." with 1 trials as a collaborator and "Pari Pharma GmbH" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Centro Ricerche Cliniche di Verona" are "COVID-19" (2 trials), "Healthy" (2 trials), "Ulcerative Colitis" (2 trials), "Active Systemic Lupus Erythematosus" (1 trials) and "Advanced Systemic Mastocytosis" (1 trials). Many other conditions were trialed in "Centro Ricerche Cliniche di Verona" in a lesser frequency.

Most popular intervention types in "Centro Ricerche Cliniche di Verona" are "Drug" (22 trials), "Biological" (3 trials), "Other" (2 trials), "Device" (1 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "Cisplatin" (3 trials), "Gemcitabine" (3 trials), "Etrasimod" (2 trials) and "GRAd-COV2" (2 trials). Other intervention names were less common.

The vast majority of trials in "Centro Ricerche Cliniche di Verona" are 22 trials for "All" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Centro Ricerche Cliniche di Verona". undefined are not yet recruiting, 10 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in Centro Ricerche Cliniche di Verona, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Centro Ricerche Cliniche di Verona, 10 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".